Drug
Sacituzumab Tirumotecan
Sacituzumab Tirumotecan: highest development phase Phase 3, developed by Merck. 8 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Merck
Trials
| Drug | Phase | Indication |
|---|---|---|
| Sacituzumab Tirumotecan NCT06459180 | Phase 3 | Cervical Cancer |
| Sacituzumab Tirumotecan NCT07216703 | Phase 3 | Cervical Cancer |
| Sacituzumab tirumotecan NCT06824467 | Phase 3 | Ovarian Cancer |
| Sacituzumab tirumotecan NCT06841354 | Phase 3 | Triple Negative Breast Neoplasms |
| Sacituzumab tirumotecan NCT07318558 | Phase 3 | Ovarian Neoplasms |
| Sacituzumab tirumotecan NCT07419295 | Phase 3 | Bladder Cancer |
| Sacituzumab tirumotecan NCT06966700 | Phase 3 | Breast Neoplasms |
| Sacituzumab tirumotecan NCT06312137 | Phase 3 | Non Small Cell Lung Cancer |
Latest
No recent events.
Follow Sacituzumab Tirumotecan on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.